Ruiao Biopharmaceutical Technology

Ruiao Biopharmaceutical Technology is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the development of innovative antibody drugs for autoimmune and allergic diseases. The company's research and development efforts are centered on high-value targets within the immunology space, including IL-17, IL-4Rα, and IL-5. Its lead candidate, RA-001, is a monoclonal antibody targeting IL-17A currently in clinical development for the treatment of plaque psoriasis. Ruiao utilizes its internal protein engineering and antibody discovery platforms to create a robust pipeline of biologics aimed at addressing significant unmet medical needs in chronic inflammatory conditions. The company is backed by prominent regional investors and is situated within the BioBAY life sciences hub.